Endometriosis-Angiopoietin-like Protein-4

Completed

• Conditions: Endometriosis; Angiopoietin-like Protein-4; Pelvic Pain

• Registration Number: NCT07164196
• Lead Sponsor: Ankara City Hospital Bilkent

Brief Summary

Endometriosis is a chronic inflammatory disease associated with pelvic pain, dyspareunia, and impaired ovarian reserve. Cancer antigen-125 (CA-125) is widely studied but limited by low specificity, while angiopoietin-like protein-4 (ANGPTL4) has emerged as a potential biomarker due to its role in angiogenesis and inflammation. In the current study it was aimed to investigate serum and peritoneal fluid ANGPTL4 levels in women with endometriosis compared to healthy controls, and to evaluate their associations with clinical symptoms, serum CA-125, and anti-Müllerian hormone levels.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-06-05
• Primary Completion: 2025-08-21
• Status Verified: 2025-09
• Study Completion: 2025-09-02
• Study First Submitted: 2025-09-02
• Study First Submitted QC: 2025-09-02
• Last Update Submitted: 2025-09-02
• Study First Posted: 2025-09-10
• Last Update Posted: 2025-09-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

• Diagnosis of endometriosis for study group who underwent laparoscopic endometriosis surgery
• Healthy women for control group

Exclusion Criteria

• Cardiovascular diseases including hypertension
• Type 1 or type 2 diabetes mellitus
• Morbid obesity
• Primary adrenal insufficiency
• Uterine fibroids
• Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease
• Hepatic dysfunctions
• Renal insufficiency
• Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9
• Neurologic diseases
• Psychiatric disorders
• Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever
• History of any malignancy
• History of exposure to chemotherapeutic agents or radiotherapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum and peritoneal fluid Angiopoietin-like protein-4 level	day 1	Nanogram/milliliter

Secondary Outcome Measures

Name	Time	Method
Serum cancer antigen 125 level	day 1	Unit/milliliter

Trial Locations

Locations (1)

Ankara Bilkent City Hospital; Ankara, Not Valid, Turkey (Türkiye)